Business
Willow Biosciences Announces Research and Development Funding for its Varin Cannabinoids
Willow Biosciences Announces Research and Development Funding for its Varin Cannabinoids ...
About this update from Atlas Energy Corp.
[{"type":"text","content":"\n\n\n\nWillow Biosciences Announces Research and Development Funding for its Varin Cannabinoids\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, BC, Sept. 8, 2020\n\n\n\nVANCOUVER, BC, Sept. 8, 2020 /CNW/ - Willow Biosciences Inc. (\"Willow\" or the \"Company\") (TSX: WLLW); (OTCQX: CANSF) is pleased to announce that its subsidiary - Willow Analytics Inc. - will receive advisory services and conditional funding from the National Research Council of Canada Industrial Research Assistance Program (\"NRC IRAP\") supporting a research and development project to advance production of its varin cannabinoids, using its proprietary biosynthetic platform. \n\n \n \n \n \n \n \n\n \n\"We welcome the advice and funding from NRC IRAP to support our rare cannabinoid development platform,\" said Dr. Mathias Schuetz, Willow's Vice-President of Research & Development. \"This support is an important catalyst for us to advance our strain development capabilities and will enable us to progress from lab-scale work to pre-commercialization scale up.\"\nWillow has built a strong reputation as a high-quality, high-purity biosynthetic cannabinoid producer. Its yeast fermentation production platform, initially developed for cannabigerol (\"CBG\") and cannabidiol (\"CBD\"), has shown impressive success and Willow expects to be the first company to biosynthetically produce material amounts of cannabinoids. By varying the feedstock used in its fermentation platform, the Company has made significant progress on developing strains for its varin series of cannabinoids and will use the NRC IRAP funding to accelerate the commercialization plan for these cannabinoids.\nTrevor Peters, Willow's President & CEO, added \"By using the platform technology that has allowed us to advance our CBG program ahead of schedule, we are able to expand our portfolio and pursue fermentation-based production of additional cannabinoids. We have made strong progress with our varins development to date and expect the varins program to reach scale-up phase in the first half of 202...